Table 2.
Characteristics of study groups.
| CAD Group (n = 169) |
Control Group (n = 166) |
p Value | |
|---|---|---|---|
| Age, years | 64.1 ± 7.7 | 62.4 ± 10.5 | 0.08 |
| Sex, male, n (%) | 124 (73%) | 108 (65%) | 0.1 |
| BMI, kg/m2 | 30.52 ± 5.3 | 28.46 ± 4.73 | 0.001 |
| WHR | 0.96 ± 0.08 | 0.92 ± 0.09 | 0.001 |
| Arterial hypertension, n (%) | 138 (83%) | 82 (56%) | 0.001 |
| Diabetes, n (%) | 50 (30%) | 16 (15%) | 0.003 |
| Current tobacco smoker, n (%) | 28 (22%) | 26 (27%) | 0.435 |
| History of tobacco smoking, n (%) | 125 (74%) | 98 (60%) | 0.005 |
| Lower limb atherosclerosis or intermittent claudication, n (%) | 12 (80%) | 3 (3%) | 0.001 |
| Hypercholesterolemia, n (%) | 137 (82%) | 69 (50%) | 0.001 |
| History of kidney disease, n (%) | 14 (9%) | 14 (11%) | 0.435 |
| Family history of the acute coronary syndrome, n (%) | 44 (30%) | 10 (7%) | 0.001 |
| Family history of stroke, n (%) | 33 (22%) | 17 (13%) | 0.037 |
| Pharmacotherapy | |||
| Use of ACE-I/ARB, n (%) | 147 (88%) | 56 (44%) | <0.001 |
| Use of beta-blockers, n (%) | 53 (31%) | 23 (18%) | 0.012 |
| Use of statins, n (%) | 150 (90%) | 38 (30%) | <0.001 |
| Use of diuretics, n (%) | 84 (50%) | 18 (14%) | <0.001 |
| Use of antiplatelet and anticoagulant treatment, n (%) | 164 (98%) | 30 (24%) | <0.001 |
| Assessments | |||
| Atherosclerotic plaques in the carotid arteries, n (%) | 163 (96%) | 123 (74%) | 0.001 |
| Heart rate in electrocardiogram, beats/minute | 62 IQR: 58–68.5 |
64.5 IQR: 58–72 |
0.044 |
| Bone Densitometry | |||
| Total fat mass, g | 29667.93 IQR: 23652.98–35995.84 |
28604.12 IQR: 20777.52–33493.96 |
0.047 |
| Android fat mass, g | 3220.41 IQR: 2510.92–4005.02 |
2849.09 IQR: 1991.26–3752.75 |
0.002 |
| Echocardiography | |||
| Left ventricle ejection fraction, % | 52.3 IQR: 47.6–57.9 |
57 IQR: 53.8–60.4 |
<0.001 |
| Left atrium diameter, mm | 39.8 IQR: 36–43.9 |
37.3 IQR: 33.2–39.7 |
<0.001 |
Mean ± standard deviation, median IQR—interquartile range, BMI—body mass index, and WHR—waist–hip ratio.